EGFL8: A Potential Drug Target and Biomarker for Epidermal Growth Factor-Like Protein 8

Target Name: EGFL8

NCBI ID: G80864

EGFL8

EGFL8: A Potential Drug Target and Biomarker for Epidermal Growth Factor-Like Protein 8

Introduction

Epidermal growth factor-like protein 8 (EGFL8) is a transmembrane protein that belongs to the EGF receptor family. It plays a crucial role in cell signaling, tissue repair, and regeneration. EGFL8 has also been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will discuss the biology of EGFL8, its potential drug targeting, and its role as a biomarker in disease diagnosis and management.

Biogenesis and Structure

EGFL8 was first identified in 2004 as a 21-kDa protein that was expressed in various tissues, including skin, heart, liver, and brain. The protein has four known isoforms, which have different molecular weight and N-terminal sequences (4 ). EGFL8 is a glycoprotein that consists of an extracellular domain, a transmembrane region, and an intracellular tail. The extracellular domain of EGFL8 consists of a unique N-terminal domain that contains a farnesylated cysteine 鈥嬧?媟esidue, which is involved in protein -protein interactions and modulation of cellular signaling pathways.

Function and Diverse Roles in Cellular Signaling

EGFL8 is a critical regulator of cell signaling, particularly in the context of cell growth, differentiation, and repair. It belongs to the EGF receptor family, which includes proteins that are involved in cell growth, angiogenesis, and plasticity. EGFL8 plays a key role in the regulation of cell proliferation, survival, and differentiation by promoting cell surface angiogenesis, promoting the formation of new blood vessels, and regulating cell-cell interactions.

EGFL8 is involved in several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. It has been shown that EGFL8 can enhance the effects of growth factors, such as TGF-β1 , and can inhibit the negative effects of mechanical stress, such as the FasL-mediated cell death. EGFL8 has also been shown to play a role in the regulation of cell adhesion, migration, and the formation of tissues.

Potential Drug Target and Biomarker

EGFL8 has been identified as a potential drug target for various diseases due to its involvement in multiple cellular signaling pathways. One of the main reasons for its potential drug targeting is its involvement in cell signaling, which makes it a promising target for agents that can modulate cell signaling pathways. For example, EGFL8 has been shown to be a potent inhibitor of the FasL-mediated cell death, which makes it a potential target for neurodegenerative diseases.

EGFL8 has also been shown to be involved in the regulation of cell adhesion and migration, which makes it a potential target for diseases that are characterized by disrupted cell-cell adhesion or migration. For example, EGFL8 has been shown to play a role in the regulation of neurotrophic factor (NTF) signaling, which is involved in the regulation of neurotrophic factors. NTF signaling is disrupted in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

EGFL8 has also been shown to be involved in the regulation of cell proliferation and survival, which makes it a potential target for diseases that are characterized by uncontrolled cell proliferation. For example, EGFL8 has been shown to play a role in

Protein Name: EGF Like Domain Multiple 8

The "EGFL8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EGFL8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets